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Physiologically based pharmacokinetic modelling (PBPK) is a powerful tool to predict in vivo pharmacokinetics based on
physiological parameters and data from in vivo studies and in vitro assays. In vivo PBPK modelling in laboratory animals by
noninvasive imaging could help to improve the in vivo-in vivo translation towards human pharmacokinetics modelling. We
evaluated the feasibility of PBPKmodellingwith PETdata frommice.Weused data from twoof our PET tracers under development,
[11C]AM7 and [11C]MT107. PET images suggested hepatobiliary excretion which was reduced after cyclosporine administration.
We fitted the time-activity curves of blood, liver, gallbladder/intestine, kidney, and peripheral tissue to a compartment model and
compared the resulting pharmacokinetic parameters under control conditions ([11C]AM7 𝑛 = 2; [11C]MT107, 𝑛 = 4) and after
administration of cyclosporine ([11C]MT107, 𝑛 = 4). The modelling revealed a significant reduction in [11C]MT107 hepatobiliary
clearance from 35.2 ± 10.9 to 17.1 ± 5.6 𝜇l/min after cyclosporine administration. The excretion profile of [11C]MT107 was shifted
from predominantly hepatobiliary (CLH/CLR = 3.8 ± 3.0) to equal hepatobiliary and renal clearance (CLH/CLR = 0.9 ± 0.2). Our
results show the potential of PBPK modelling for characterizing the in vivo effects of transporter inhibition on whole-body and
organ-specific pharmacokinetics.
1. Introduction
Clinical drug-drug interactions result in many cases from
an inhibition of drug-transporting proteins in the liver
or kidney [1–4]. Hepatocytes express a variety of drug-
relevant transporter proteins. Transporters such as OATP1B1
(encoded by SLCO1B1) and OATP1B3 (SLCO1B3) can facili-
tate drug entry into the hepatocytes and, therefore, promote
drug metabolism. Efflux transporters, such as P-glycoprotein
(ABCB1) and BCRP (ABCG2), can transport their substrates,
including drugs and their metabolites, from the hepatocytes
into bile, which is secreted into the small intestine [2]. Inhi-
bition of drug-transporting proteins can consequently reduce
both drug metabolism and drug or metabolite excretion into
bile.
In the glomeruli of the kidneys, drugs are filtrated out
of the plasma into the primary urine. Lipophilic drugs are
reabsorbed from the tubuli upon the concentration of the pri-
mary urine. In addition to filtration/reabsorption, transport
proteins in the proximal tubuli can promote the transport
of drugs from blood into urine [2]. The renal clearance
(CLR) results from glomerular filtration, reabsorption, and
tubular secretion. Transporter inhibition may thus reduce
CLR besides hepatobiliary clearance (CLH).
Whether a drug is a substrate and/or an inhibitor of a
particular transporter protein can be studied in vitro with
transporter-overexpressing cells [5, 6]. However, the in vivo
consequences are not always easy to predict. Physiologically
based pharmacokinetic modelling (PBPK) to predict in vivo
kinetics based on in vitro data requires detailed information
Hindawi
Contrast Media & Molecular Imaging
Volume 2018, Article ID 5849047, 11 pages
https://doi.org/10.1155/2018/5849047
2 Contrast Media & Molecular Imaging
N
N
NHN
NH
N
O
O
F
N
NHN
NH
N
O
O
F
11＃（3
11＃（3
Molecular weight: 419.45 Molecular weight: 562.56
＃＆3
[11C]AM7 [11C]MT107
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on the expression levels and activity of individual transport
proteins in both the in vitromodel and the in vivo organisms
[7, 8]. Information is particularly limited for laboratory
animals as rodent transporter-overexpressing cells and in
vitro-in vivo weighting functions for modelling are scarcely
available [9, 10].
Dynamic noninvasive imaging by positron emission
tomography (PET) or single photon emission computed
tomography (SPECT) allows assessing the hepatobiliary or
renal clearance of a suitable tracer in humans and laboratory
animals. In most cases, the data are analysed with simpli-
fied, robust models, focusing on one particular elimination
process. Clinical examples are the evaluation of transporter-
mediated hepatocyte uptake and efflux into bile with (15R)-
[11C]TIC-Me or the conjugated bile acid tracer [11C]CSar
[11, 12]. We explored the possibility of studying the effects
of transporter inhibition on the overall pharmacokinetics of
a radiolabelled molecule by PET in mice. PET allows gen-
erating well-defined tissue radioactivity concentration time
curves (C(t)) from image data. In addition, blood can be sam-
pled to measure the blood C(t) simultaneously [13, 14]. PET
kinetic modelling is a standard method for the quantifica-
tion of brain function, for example, glucose consumption or
neuroreceptor density in preclinical and clinical imaging [13–
15].Here, we shift the focus of PETkineticmodelling from the
study of an individual process or organ to in vivowhole-body
PBPK modelling in mice.
In this feasibility study, we repurposed mouse PET data
gathered with our PET tracers under development [11C]AM7
and [11C]MT107, both targeting the human costimulatory
molecule CD80 (hCD80) [16] (Taddio et al., in preparation;
Figure 1). CD80 is a surface protein on activated antigen-
presenting cells (APCs). Upon antigen presentation, its
interaction with CD28 activates T cells while binding to
CTLA-4 inactivates T cells and depletes CD80 from the cell
surface of the APCs [17, 18]. By targeting CD80, we aim to
image elevated immunogenic activity, for example, in cancer,
atherosclerosis, or autoimmune diseases. In our previous
work with [11C]AM7, we observed high biliary excretion of
radioactivity resulting in high radioactivity spill-over from
the abdomen. The tracer furthermore showed low tissue
uptake, in agreement with its low lipophilicity, log𝐷 (pH 7.4)
of 0.1, and low unbound fraction in plasma (𝑓u) 0.02 [16]. As
a consequence, accumulation in hCD80-positive xenografts
was negligible. The structurally modified [11C]MT107 (Fig-
ure 1), based on structures by Green et al. [19] and Huxley
et al. [20], had a similar strong affinity in the low nanomolar
range to the imaging target hCD80 as [11C]AM7. Its log𝐷 (pH
7.4) was higher with 2.0 and albumin binding was similar to
that of [11C]AM7 (Taddio et al., in preparation). PET images
showed higher tissue radioactivity compared to [11C]AM7
but still high abdominal radioactivity accumulation. In this
study, we investigated the pharmacokinetics of the two tracers
by in vivo PBPK modelling and studied the effects of trans-
porter inhibition by cyclosporine on the pharmacokinetics of
[11C]MT107.We show that in vivo PBPKmodelling in mice is
possibly based on dynamic whole-body PET data.
2. Materials and Methods
2.1. Small Animal PET with [11C]AM7 and [11C]MT107.
[11C]AM7 and [11C]MT107 (Figure 1) were synthesized as
described previously for [11C]AM7 [16]. The synthesis of the
precursor for [11C]MT107 was based on Green et al. (2003)
and a patent from 2004 [19, 21] (Taddio et al., in prepara-
tion). Molar activities at the end of synthesis were between
200 and 500GBq/𝜇mol for [11C]AM7 and between 20 and
80GBq/𝜇mol for [11C]MT107.
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Animal experiments were in accordance with the Swiss
legislation on animal welfare and approved by the Veterinary
Office of the Canton Zurich, Switzerland. For this study,
we used PET data from 7-to-10-week-old female C.B.17
SCID or CD1 nude mice (16.9–21.2 g body weight; Charles
River, Sulzberg, Germany), carrying hCD80-positive Raji
xenografts according to [16, 22]. Raji cells were from DSMZ
(Braunschweig, Germany). The xenograft-related results will
be published elsewhere (Taddio et al., in preparation). As
the radioactivity fraction in the xenografts was negligible
compared to the total radioactivity dose, tracer distribution
to the xenograftswas not taken into account in themodelling.
For PET/CT acquisition, mice were anaesthetized with 3
to 5% isoflurane in air/oxygen (1 : 1), at a respiratory rate of ∼
60 permin as described elsewhere [16]. Cyclosporine (50mg/
kg), to inhibit cyclosporine-sensitive transporters, was inject-
ed into a tail vein (i.v.), 30 to 50min before tracer injection
while the respective tracer was synthesized. The injected
cyclosporine solution was a dilution with water for injec-
tion (1 : 1) of Sandimmun (Novartis Pharmaceuticals, Basel,
Switzerland; 50mg/ml cyclosporine in 26.1% ethanol/65%
PEG-35 castor oil). Vehicle (13% ethanol, 2ml/kg) was
injected as a control as indicated. Immediately after radiosyn-
thesis quality control, the tracer was injected i.v. at a dose
between 3 and 14MBq (<20 nmol/kg) in 100 to 200𝜇L saline
containing 5% ethanol. Injections lasted ∼10 s. The mouse
was transferred to a SuperArgus PET/CT scanner (Sedecal,
Madrid, Spain, formerly Vista eXplore) with an axial field
of view of 4.8 cm and a spatial resolution of 1.6–1.7mm
(full width at half maximum; [23]). Body temperature and
respiratory rate were controlled as previously described [16].
The PET scan was started in List mode 60 s after tracer
injection. After 60min scan duration, computed tomography
(CT) data were recorded for anatomical orientation.
Two mice were scanned with [11C]AM7 under control
conditions (with vehicle injection) and one was scanned with
[11C]AM7 after cyclosporine administration. Group sizes for
[11C]MT107were 𝑛 = 4 for control conditions (onewith vehi-
cle and three without vehicle) and 𝑛 = 4 after cyclosporine
administration. At the end of the PET and CT scans, the
mice were euthanized by decapitation, still under isoflurane
anaesthesia, and two [11C]AM7 and one [11C]MT107 mice
were dissected to measure tissue radioactivities in a gamma
counter (1480 Wizard 3󸀠󸀠, Perkin Elmer).
ThePETdatawere reconstructed into 10 or 12 time frames
by 2D Fourier rebinning/ordered-subsets expectation maxi-
mization (FORE/OSEM), 2 iterations, and 16 subsets, correct-
ing for singles and randoms but not attenuation. Images were
generated with the software PMOD v3.8 (PMOD, Zurich,
Switzerland). All radioactivities were decay-corrected to the
time point of tracer injection.
2.2. Time-Activity Curves. Theblood𝐶(𝑡)was generated with
PMOD from the PET images as follows. A cropped cube of
10 × 10 × 10mm3 including the image data of the heart was
divided into 12 segments with differing kinetics, using the
PSEG module of PMOD. 𝐶(𝑡) of the segment covering the
left heart ventricle according to the PET (first time frame)/CT
imageswas used as an estimation of the blood𝐶(𝑡) (𝐶Blood(𝑡)).𝐶Blood(𝑡)was divided by (1 − hematocrit) to get𝐶Plasma(𝑡) and
fitted to a biexponential infusion function as shown in
𝐶Plasma (𝑡) = 𝐴 (0)𝑇 × 𝑉1 × [
(𝜆1 × 𝑉1) /𝑉𝑧 − 𝜆1𝜆1 (𝜆𝑧 − 𝜆1)
× (1 − 𝑒−𝜆1×[𝑡(𝑡≤𝑇)+𝑇(𝑡>𝑇)]) × 𝑒−𝜆1×(𝑡−𝑇)(𝑡>𝑇)
+ (𝜆1 × 𝑉1) /𝑉𝑧 − 𝜆𝑧𝜆𝑧 (𝜆1 − 𝜆𝑧) × (1 − 𝑒−𝜆𝑧×[𝑡(𝑡≤𝑇)+𝑇(𝑡>𝑇)])
× 𝑒−𝜆𝑧×(𝑡−𝑇)(𝑡>𝑇)] ,
(1)
where 𝐴(0) is the radioactivity dose, 𝑇 is the duration of
the injection (10 s infusion), 𝑉1 is the volume of the central
compartment (initial volume of distribution of the tracer
after injection), 𝑉𝑧 is the volume of distribution during
the terminal phase, and 𝜆1 and 𝜆𝑧 are the respective rate
constants of the biexponential function and 𝑡 the time [24].
The term [𝑡(𝑡 ≤ 𝑇) +𝑇(𝑡 > 𝑇)] equals 𝑡 if 𝑡 ≤ 𝑇 but 𝑇 if 𝑡 > 𝑇.
The term (𝑡 − 𝑇)(𝑡 > 𝑇) equals 𝑡 − 𝑇 if 𝑡 > 𝑇, otherwise zero.
The hematocrit was assumed 0.44 [25, 26].
Total plasma radioactivity (𝐴Plasma(𝑡)) was estimated as
the product of the image-derived𝐶Blood(𝑡) and the theoretical
blood volume (VBlood 0.0585ml per g body weight, BW [25])
multiplied with BW. Blood-related data may be biased by
radioactivity spill-over and partial volume effects.𝐶(𝑡) of liver, kidneys, and peripheral tissue and 𝐴(𝑡) of
gallbladder and intestines were derived frommanually drawn
volumes of interest according to the PET/CT images, using
the VOI functions of PMOD. Regions of interest are shown
for a representative scan in Supplementary Figure 1.𝐶(𝑡) data
were transformed to𝐴(𝑡) by multiplication with the reported
average volume of the respective organ or tissue. These were
0.065 cm3 per g BW for liver and 0.0164 cm3 per g BW for
kidneys [26]. The volume of the “peripheral tissue” (𝑉Tissue)
with 𝐶(𝑡) determined from the left shoulder was estimated
during the fitting procedure. It was 0.74 ± 0.08 cm3 per g
BW for [11C]MT107 control scans and 0.79 ± 0.10 cm3/g
for [11C]MT107 scans after cyclosporine treatment, without
significant difference (𝑝 = 0.47).
2.3. Pharmacokinetics Model and Nonlinear Least-Squares
Curve Fitting. 𝐴(𝑡) of the individual regions of interest were
fitted with custom-written MATLAB scripts (MathWorks,
Natick, MA) according to the compartment model shown in
Figure 2, using the ode45 function to solve the differential
equation system. Tracer input was simulated as a constant
input of duration 𝑇 (𝐴(0)/𝑇). Fitting was performed with
the solver fmincon and the function MultiStart with 128
random sets of bounded initial parameters. Calculationswere
performed by parallel computing on 40 cores of the Euler
cluster of ETH Zurich (https://scicomp.ethz.ch/). The initial
parameters were best guesses from supervised simulations.
Initial lower bounds were 0 for the rate constants of mass
transfer (𝑘). For 𝑘 fromplasma to liver and kidneys, the initial
upper bounds were set according to the reported values for
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Figure 2: Model for the pharmacokinetic analysis.𝐴(0) is the dose, and𝑇 is the infusion duration (10 s). Initial𝐴(𝑡 = 0) for all compartments
(indicated by black boxes) were zero. The parameters 𝑘 are mass transfer rate constants with the unit 1/time. The indices denote the source
and target compartments, respectively (e.g., 𝑘BH1 , 𝑘 for the mass transfer from blood plasma to hepatic compartment “Liver 1”). 𝐴(𝑡) of
peripheral tissue was best fit with two sets of rate constants for reversible transfer. The sum of the two plasma-to-tissue rate constants is 𝑘BT.
Several models were evaluated and the results were visually inspected.The shownmodel revealed reliable fits as concluded from the robust fit
parameters and the visual inspection of the plotted fit functions. For [11C]MT107 scans, 𝑘BG (grey arrow) was set to 0. Tissue blood fractions
(VBlood multiplied with the organ or tissue volume and 𝐶Blood(𝑡)) were added to the compartments where applicable. B, blood plasma; G,
gallbladder plus intestine combined; H, liver; R, kidneys; T, peripheral tissue; U, urine.
blood flow [26], corrected for (1 − hematocrit) to get the
plasma flow (𝑄P) divided by the plasma volume (𝑉Plasma =
VBlood × (1 − hematocrit) × BW). The 𝑄P for liver (𝑄P,H) was
1.0ml/min and for kidneys (𝑄P,R) 0.73ml/min.
During the fitting procedure, the sum of weighted
squared residuals of all 𝐴(𝑡) was minimized. For weighting,
the residuals of the first two data points of plasma, liver, and
kidney were multiplied with 5, to force the fits through these
initial data points. After several rounds, the best estimates
with the lowest sum of squared residuals were used per
tracer to define the final upper and lower bounds as 0.5-
fold the minimal respective fit parameter and 2-fold the
highest respective fit parameter per tracer. This resulted in
reproducible fit parameters at a minimal sum of squared
residuals for all scans. Under these refined conditions, one
calculation (one scan) with 128 random sets of initial values
required 10–120min.
CLH was calculated according to
CLH = 𝑘BH1 × 𝑘H1H2(𝑘H1B + 𝑘H1H2) × 𝑉Plasma, (2)
where the rate constants 𝑘 are defined in the model in
Figure 2. Note that at steady state this equals CLH calculated
from 𝑘H2G.
To calculate CLR, the compartments R1 and R2 were
treated as one compartment to reveal (3) in analogy to the
previously suggested simplifications [27, 28].
CLR = 𝑘BR1(𝑘R1B + 𝑘R1U) / (1 + 𝑘R1R2/𝑘R2R1)
∗ 𝑘R1U(1 + 𝑘R1R2/𝑘R2R1) × 𝑉Plasma.
(3)
The term 1/(1 + 𝑘R1R2/𝑘R2R1) corrects for the mass ratio
between R1 and the combined R1 and R2.
Total CL was calculated as the sum of CLH and CLR
and compared to the CL estimated from the 𝐶Plasma(𝑡)
biexponential fits (see (1)), as CL = 𝜆𝑧 × 𝑉𝑧. The extraction
ratio 𝐸H for liver was estimated as ratio between CLH and𝑄P,H, with 𝑄P,H from Davies and Morris [26].
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Figure 3: PET images (maximal intensity projections) of mice with (a) 13.9MBq [11C]AM7 and (b) 12.5MBq [11C]AM7 after cyclosporine
administration (50mg/kg i.v.). Radioactivity in the images (𝐶(𝑡)) was normalized to𝐴(0)/BW (standardized uptake value, SUV) and averaged
for the complete scan duration of 60min. G, gallbladder; H, heart; I, intestines; K, kidney; L, liver; U, urinary bladder. CD1 nu/nu mice.
The distribution coefficient between tissue and plasma at
equilibrium (𝐷Tissue) was calculated according to
𝐷Tissue = (𝑓BT1 × 𝑘BT𝑘TB1 +
(1 − 𝑓BT1) × 𝑘BT𝑘TB2 )
× 𝑉Plasma𝑉Tissue .
(4)
2.4. Statistics. Fit parameters of the individual conditions
were compared by homoscedastic 2-tailed Student’s 𝑡-test and
differences were defined as significant at 𝑝 < 0.05.
3. Results
3.1. PET Imageswith [11C]AM7and [11C]MT107. PET images
(maximal intensity projections) of [11C]AM7 averaged over
the complete scan duration are shown in Figure 3. Under
control conditions, [11C]AM7 radioactivity accumulated in
the liver, gallbladder, intestines, and the urinary bladder
while the radioactivity in peripheral tissues was negligible
(Figure 3(a)). The high radioactivity in gallbladder and
intestines is typical for transporter-mediated efflux into bile.
The radioactivity distribution changedwhen cyclosporine, an
inhibitor of several human and rodent hepatic transporters,
such as P-glycoprotein, OATP1B1, OATP1B3, and BCRP [29],
was administered before the tracer. The radioactivity was
increased in kidneys and peripheral tissue and reduced in
liver, gallbladder, and intestines (Figure 3(b)), indicating a
reduction in CLH by cyclosporine.
The findings were similar for the [11C]AM7 derivative
[11C]MT107. Figure 4 shows PET images (maximal intensity
projections) of [11C]MT107 over time. Cyclosporine admin-
istration before the injection of [11C]MT107 resulted in an
increased radioactivity uptake in the kidneys and peripheral
tissue and reduction in the liver as compared to scans
without cyclosporine. The respective images averaged over
the complete scan duration are shown in Supplementary
Figure 2.
3.2. Kinetics of the Tracers in Blood Plasma. Figure 5 shows𝐶Plasma(𝑡) as derived from the PET images with the respective
biexponential fits (see (1)) for [11C]AM7 and [11C]MT107
under baseline conditions and after the administration of
cyclosporine. The fit parameters are shown in Table 1. Note
that 𝐶Plasma(𝑡)may be underestimated and𝑉1 and𝑉𝑧 accord-
ingly overestimated, due to radioactivity spill-over and partial
volume effects (see Section 2.2). However, we did not find a
major disagreement between the blood radioactivity of the
last image time window and as determined from the dis-
section experiments (Figures 6(a), 7(h) and Supplementary
Figure 3).
For both tracers, 𝜆𝑧 was reduced in the presence of
cyclosporine resulting in a prolonged half-life (𝑡1/2 = ln(2)/𝜆𝑧), significant for [11C]MT107 (Table 1).TheCLwas reduced
by trend, but not at the significance level (𝑝 = 0.23). For
[11C]MT107, it was 56.1±1.3 𝜇l/min under control and 45.0 ±1.0 𝜇l/min under cyclosporine conditions. For comparison,
the maximal expected CL by glomerular filtration would
be ∼160 𝜇l/min, the maximal possible CLH ∼1000 𝜇l/min,
and the maximal CL by renal filtration with additional
transporter-mediated renal excretion∼730 𝜇l/min, according
to the reported respective values for 𝑄P [26].
3.3. Physiologically Based Pharmacokinetic Modelling. We
first evaluated the modelling according to the model in Fig-
ure 2 with data from a control [11C]AM7 scanwhich included
the complete urinary bladder and for which data from dissec-
tion were available (scan in Figure 3(a)). We found a good
agreement between the fitted and the experimental data
(Figure 6). 𝐴urine(𝑡) as derived from the PET images was not
used for the fitting, as it was not available in the remain-
ing data sets. The good agreement between the predicted𝐴urine(𝑡) from the modelling and the experimental data
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Figure 4: PET images over time of [11C]MT107 (SUV, maximal intensity projections). (a) Control scan, 7.1MBq [11C]MT107. (b) Scan after
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Figure 5: SUV plasma curves of [11C]AM7 and [11C]MT107 as derived from the PET images. (a) Control (circles, [11C]MT107, 𝑛 = 4; squares,
[11C]AM7, 𝑛 = 2). (b) After cyclosporine treatment (𝑛 = 4 for [11C]MT107; 𝑛 = 1 for [11C]AM7). Lines, biexponential fits according to (1).
Colours distinguish individual data sets. Fit parameters; see Table 1.
further confirmed the accuracy of themodelling. In addition,
results from the two [11C]AM7 control scans were consistent
(Figure 6, Table 1). Compared with the results from the dis-
section, radioactivities of liver and combined gallbladder and
intestines were underestimated from the PET images while
tissue radioactivity was higher from the PET images (shoul-
der, Supplementary Figure 1) than the dissection (vastus
lateralis and rectus femoris). The fit parameters are shown in
Table 1 and Supplementary Table 1.The data of the [11C]AM7
scan after cyclosporine administration shown in Figure 3(b)
were not suitable for modelling as 𝐶kidney(𝑡) was poorly
defined (Supplementary Figure 3 and SupplementaryTable 1).
Figure 7 shows the image-derived 𝐴(𝑡) and computed
fits for [11C]MT107 under control conditions and after
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Figure 6: Experimental and fit 𝐴(𝑡) of [11C]AM7 under control conditions. (a) Scan with available image data for urine and with blood and
tissue data from dissection. (b) Scan without control data from dissection and no complete urinary bladder in the images. Circles, image data;
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Table 1: Plasma pharmacokinetics and PBPK modelling results based on [11C]AM7 and [11C]MT107 PET data.
[11C]AM7 [11C]MT107
Control (𝑛 = 2)a Cyclosporine (𝑛 = 1)a Control (𝑛 = 4)a Cyclosporine (𝑛 = 4)a
Body weight (g) 24.4/19.7 25.3 19.0 ± 2.4 20.2 ± 1.1
Plasma kinetics (Equation (1))𝑉1 (ml) 3.0/2.3 4.2 1.49 ± 0.19 1.38 ± 0.11𝑉𝑧 (ml) 10.3/9.4 8.0 2.66 ± 0.51 3.33 ± 0.80𝜆1 (1/min) 0.196/0.295 0.204 0.121 ± 0.011 0.139 ± 0.021𝜆𝑧 (1/min) 0.0234/0.0270 0.0206 0.0210 ± 0.0011 0.0140 ± 0.0034∗∗b
CL (𝜇l/min) 242/253 165 56.1 ± 13.0 45.0 ± 10.1
In vivo PBPK modelling
CLH (𝜇l/min) 103 (18.3%)c/120 (5.8%)c n.d.d 35.2 ± 10.9 17.1 ± 5.6∗b𝐸H (-) n.d. 0.035 ± 0.011 0.017 ± 0.006∗b
CLR (𝜇l/min) 161/179 n.d. 11.9 ± 5.3 19.9 ± 5.1
CLR/GFR (-) 1.0/1.1 n.d. 0.074 ± 0.033 0.12 ± 0.03
CLH/CLR (-) 0.64/0.63 n.d. 3.8 ± 3.0e 0.9 ± 0.2f
CL (𝜇l/min) 264/298 n.d. 47.1 ± 11.9 37.0 ± 8.9𝐷Tissue (-) 0.11/0.12 n.d. 0.10 ± 0.02 0.14 ± 0.03
PBPK parameters were calculated from the fitted k according to (2) and (3) and the model in Figure 2. aIndividual values for [11C]AM7 and mean with
standard deviations for [11C]MT107; n, number of scans; bsignificant decrease compared to [11C]MT107 control; cfor [11C]AM7, CLH includes 𝑘BG ×𝑉Plasma
(% contribution shown in brackets; see Figure 2) dn.d., not determined; eall ratios > 2.0; f all ratios < 1.1. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
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(h), available experimental data from dissection at the end of the scan (68min). Lines, modelled 𝐴(𝑡). Colours and line style, see Figure 6.𝐴(0) and BW are indicated in the panels. The respective 𝐶(𝑡) curves are shown in Supplementary Figure 4. SCID mice.
cyclosporine treatment. The respective 𝐶(𝑡) are shown in
Supplementary Figure 4. For one scan (Figure 7(h)), data
from dissection were available indicating an underestima-
tion of intestinal radioactivity in the images. As concluded
from Figure 7, the accumulation in liver was reduced after
cyclosporine treatment. Under control conditions, the image-
derived 𝐴(𝑡) for the combined gallbladder and intestines
exceeded the modelled 𝐴urine(𝑡). This was not the case after
cyclosporine treatment. This indicates that the radioactivity
was mainly cleared by hepatobiliary excretion under control
conditions but not after cyclosporine treatment.
The fit parameters of [11C]AM7 and [11C]MT107 are
shown in Table 1 and Supplementary Table 1. Under control
conditions, CLH was in the range of 100 𝜇l/min for [11C]AM7
and 35.2 ± 10.9 𝜇l/min for [11C]MT107.This is low compared
to 𝑄P,H, the maximal possible CLH (∼1000 𝜇l/min). As a
consequence, the values of𝐸H were low for both tracers. After
cyclosporine treatment, CLH and 𝐸H of [11C]MT107 were
significantly reduced to 48% of the respective values in the
absence of cyclosporine (Table 1). For 𝐸H, this corresponded
to an averaged reduction from 0.035 ± 0.011 to 0.017 ± 0.006
(𝑝 = 0.025).
The CLR calculated for the two [
11C]AM7 control scans
was in the range of the reported glomerular filtration rate
(GFR) of 160 𝜇l/min [26]. In the case of [11C]MT107, it was
lower than the GFR with CLR/GFR fractions <0.2 for all
scans. CLR/GFR < 1 could result from a reduced filtration due
to plasma protein binding or from reabsorption of the tracer
after glomerular filtration. A difference in renal reabsorption
between [11C]AM7 and [11C]MT107 would be expected from
their difference in lipophilicity, that is, log𝐷 (pH 7.4) 0.1
versus 2.0 [30].
After cyclosporine administration, CLR of [
11C]MT107
was increased 1.7-fold on average, though not at the sig-
nificance level (𝑝 = 0.069). As a consequence of the
significant reduction in CLH and tentative increase in CLR
after cyclosporine treatment, the averaged ratio CLH/CLR
decreased from 3.8±3.0 to 0.9±0.2 (𝑝 = 0.11).The excretion
pattern changed from preferentially hepatobiliary to similar
contributions from both hepatobiliary and renal pathways.
For both tracers, the fits were best when including an irre-
versible besides a reversible uptake into liver (Figure 2) with
radioactivity excretion from the irreversible compartment to
gallbladder and intestine. The fits and results were similar
if the two compartments were in parallel, both adjacent to
the plasma compartment (data not shown). For the kidneys,
two reversible compartments revealed best fits with excretion
into urine from the compartment adjacent to plasma. As
observed for liver, the fits and results were similar when
the kidney compartments were arranged both adjacent to
the plasma compartment (data not shown). The irreversible
uptake into the liver before excretion is in agreement with
transporter-mediated irreversible uptake into hepatocytes
or efflux into the canaliculi. For kidney, the two reversible
compartments could reflect reversible distribution into the
kidneys and glomerular filtration for compartment R1 and
tracer accumulation by the concentrating primary urine and
reabsorption from the tubuli for compartment R2.
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Besides the tentative increase in CLR, the average 𝐷Tissue
of [11C]MT107 was nonsignificantly increased by a factor of
1.34 after cyclosporine administration (𝑝 = 0.078), in agree-
ment with the trend of 𝑉𝑧, which increased 1.25-fold (𝑝 =0.21). Besides transporter inhibition, cyclosporine can dis-
place drugs from plasma protein binding [31, 32]. An increase
in 𝑓u of [11C]MT107 would explain both the increase in𝐷Tissue and in CLR. We did not further investigate this since
the effects on CLR and 𝐷Tissue were not significant. The
relatively high CLR of [
11C]AM7 in the range of the GFR
would indicate that𝑓u is not limiting for glomerular filtration,
at least for [11C]AM7.
In our model, 𝑘GH1 is the rate constant of reabsorption
from intestines by portal vein into the reversible compart-
ment of the liver (H1 in Figure 2). We hypothesized that
inhibition of efflux transporters in the intestinal mucosa by
cyclosporine may increase reabsorption and, therefore, 𝑘GH1 .
However, the averaged 𝑘GH1 for [11C]MT107 in the absence
and presence of cyclosporine did not differ, theywere 0.0077±0.0033min−1 and 0.0080 ± 0.0038min−1, respectively (𝑝 =0.90). The simulated reabsorbed fractions of [11C]MT107 are
indicated in Figure 7. It should, however, be noted that 𝑘GH1
could alternatively or in addition compensate forA(t) under-
or overestimations, in particular as image-derived 𝐴(𝑡) and𝐴(𝑡) from dissection were not in full agreement.
In the above calculations, 𝑘BG, defining the transintestinal
excretion from plasma to intestines, was set to 0 (Figure 2).
When 𝑘BG was fitted for [11C]MT107 scans, average CLH
(ml/min) were 25.4 ± 6.0 under control conditions and 9.3 ±4.2 after cyclosporine administration with a significant dif-
ference (𝑝 = 0.0045).The calculated transintestinal clearance
(ml/min) varied between the scans with 10.5 ± 11.3 for the
control and 7.8 ± 4.1 for the cyclosporine group (𝑝 = 0.67).
The sum of the individual CLH and transintestinal clearance
was similar to the CLH calculatedwith 𝑘BG = 0, including 𝑘BG
in the model improved the fit of liver 𝐴(𝑡) in Figure 7(a).
The modelling revealed a 16% (control group) and 17%
(cyclosporine group) lower total CL of [11C]MT107 than
the biexponential fit of 𝐶Plasma(𝑡) (Table 1). The differences
between the two methods were not significant (𝑝 > 0.27).
They could result from an overestimation of 𝑉𝑧 as discussed
in Section 2.2 and from errors in estimating 𝐴(𝑡) for the
individual organs and tissues from the image data in general,
as several assumptions were made on organ and tissue
volumes and as PET data are biased by partial volume effects
and radioactivity spill-over [33].
4. Discussion
We demonstrated that PBPK modelling is feasible with
dynamic mouse PET data. In our case, we apply this analysis
to guide the further development of [11C]AM7-derived PET
tracers for the purpose of imaging hCD80 levels by PET. We
suggest that this method can further be used to study the
influence of drugs on transporter activity and on the pharma-
cokinetics in general, by applying PET tracers which are sub-
strates of the saturable pharmacokinetic process of interest.
Besides these applications, PBPK modelling in combination
with nuclear imaging was successfully demonstrated for
177Lu-DOTATATEused for therapy in patientswith neuroen-
docrine tumours [34]. The authors suggested to apply PBPK
to model the biodistribution and absorbed radiation doses of
therapeutic radiotracers in the healthy and tumour tissues of
patients in order to better evaluate the risk/benefit balance
and find the optimal radioactivity dose for tumour treatment.
Several protocols exist to evaluate hepatobiliary excre-
tion, and transporter activity by PET or SPECT [11, 35].
These methods use simplified models, possibly revealing
more robust results and requiring less computing capacity
than the full-compartment modelling presented here. In
contrast to the simplified models which focus on one par-
ticular organ and its function, full compartment modelling
allows identifying distinct alterations in a more complex
model where all relevant processes can be included, for
example, tissue distribution and renal excretion in addition
to hepatobiliary excretion, as in the presented example. To
assure the applicability of our model, we kept the number
of compartments and rate constants to a minimum, while
keeping focus on reliable fitting results.
For this study, we repurposed data from previous PET
experiments. The experiments were not originally designed
for PBPK modelling. For this reason, we encountered some
limitations which have to be taken into consideration when
planning a PBPK study by PET. (i) Based on the design of our
control experiments, we cannot exclude that the adjuvants
in Sandimmun had an influence on the pharmacokinetics
of our tracers. (ii) The first minute after tracer injection is
not included in our experimental data. This time window
is essential for the accurate modelling of rate constants
between plasma and tissues. (iii) Having the urinary bladder
in the field of view would allow estimating the amount of
radioactivity in urine and comparing it with the modelling
results or include it in the fitting. Depending on the size of
the field of view, this is not always possible. In our study,
we used the available data of urinary bladder of one scan to
evaluate the modelling and found a good agreement between
the predicted and experimental data. (iv) Owing to the small𝑉1 and 𝑉𝑧 of the two tracers, we were able to estimate𝐶Blood(𝑡) from the image data. Ideally,𝐶Blood(𝑡) is determined
from an arteriovenous shunt to avoid bias by partial volume
effects and radioactivity spill-over and to get a high temporal
resolution [13, 36]. (v) A further limitation of this study is the
low number of animals scanned with [11C]AM7 where two
scans were available for control conditions and no reliable
data was available to study the influence of cyclosporine by
PBPK modelling. Therefore, no statistical analysis could be
applied to compare the two tracers.
Tracer metabolism should be negligible when studying
transporter activity. In particular, as cyclosporine is not
only an inhibitor of drug transporters but also of the
drug-metabolising enzyme CYP3A4 in humans [29]. Radio-
metabolite formation would complicate the modelling. No
radiometabolites were detected in the blood plasma 30min
after [11C]AM7 administration in our previous study [16].
Demethylation of the [11C]methyl group of both trac-
ers by cytochrome P450 would be the most probable
radiometabolite-forming reaction [37, 38]. The resulting
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radiometabolite [11C]formaldehyde or its oxidation and
reduction products would accumulate in bone marrow and
salivary gland besides liver [39]. We did not find such
radioactivity distribution in our PET images, excludingmajor
[11C]demethylation of the tracers.
As pointed out by Stieger et al. [35], studies as presented
here can contribute to a better understanding of the mecha-
nisms of drug-drug interactions and can provide information
for the generation of model parameters for PBPK modelling
based on in vitro data. In the future, rodent and human
PET with dedicated tracers will support the building and
refinement of PBPK models to facilitate the translation from
in vitro to the in vivo preclinical phase and to support the
prediction of the pharmacokinetics in humans based on
preclinical and clinical data. Besides a calibrated PET scanner
with high spatial resolution, high computing capacity and
parallel computing are favourable for successful modelling.
5. Conclusions
By PBPK modelling using dynamic PET data from mice,
we were able to characterize distinct pharmacokinetic details
for two structurally related radiotracers. Our modelling
approach allowed identification of the pharmacokinetic alter-
ations induced by the transporter inhibitor cyclosporine.
Our study shows the potential of PBPK modelling with PET
data for radiotracer and drug development, as well as for
evaluating and predicting the effects of transporter inhibition
on whole-body pharmacokinetics.
Data Availability
Raw data and metadata of the PET scans as well as the
MATLAB scripts are available from the corresponding author
on request. Data are still under evaluation by the authors for
other purposes (Taddio et al., in preparation).
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this article.
Acknowledgments
The authors thank Bruno Mancosu for his commitment with
radiotracer synthesis, Adrienne Mu¨ller Herde for her great
scientific support, and Henriette Meyer zu Schwabedissen
(University of Basel, Switzerland), Mohammed Ullah (F.
Hoffmann-La Roche Basel, Switzerland), and Bruno Stieger
(University of Zurich, Switzerland) for fruitful discussions
about transporter physiology.Thisworkwas supported by the
Swiss National Science Foundation (SNSF) [153352] and by
the KFSP Molecular Imaging Network Zurich (MINZ).
Supplementary Materials
Supplementary PDF file includes the following: (i) Sup-
plementary Figure 1: volumes of interest for the kinetic
modelling. (ii) Supplementary Figure 2: PET images (max-
imal intensity projections) of mice with [11C]MT107 and
[11C]MT107 after cyclosporine administration (50mg/kg
i.v.). The same data as in Figure 4 but averaged for the com-
plete scan duration. (iii) Supplementary Figure 3:𝐴(𝑡) exper-
imental data and fits of the [11C]AM7 scan after cyclosporine
treatment in Figure 3(b). (iv) Supplementary Figure 4: 𝐶(𝑡)
of the scans and fits in Figure 7. (v) Supplementary Table 1: fit
parameters. (Supplementary Materials)
References
[1] J. Ko¨nig, F. Mu¨ller, and M. F. Fromm, “Transporters and drug-
drug interactions: important determinants of drug disposition
and effects,” Pharmacological Reviews, vol. 65, no. 3, pp. 944–
966, 2013.
[2] M. J. Zamek-Gliszczynski, X. Chu, J. W. Polli, M. F. Paine, and
A. Galetin, “Understanding the transport properties of metabo-
lites: Case studies and considerations for drug development,”
Drug Metabolism and Disposition, vol. 42, no. 4, pp. 650–664,
2014.
[3] X. Huo and K. Liu, “Renal organic anion transporters in
drug–drug interactions and diseases,” European Journal of
Pharmaceutical Sciences, vol. 112, pp. 8–19, 2018.
[4] Y. Shitara, T. Itoh, H. Sato, A. P. Li, and Y. Sugiyama, “Inhibition
of transporter-mediated hepatic uptake as a mechanism for
drug-drug interaction between cerivastatin and cyclosporin A,”
The Journal of Pharmacology and Experimental Therapeutics,
vol. 304, no. 2, pp. 610–616, 2003.
[5] S. Y. Chang, E. J. Weber, K. P. Van Ness, D. L. Eaton, and E. J.
Kelly, “Liver and Kidney on Chips: Microphysiological Models
to Understand Transporter Function,” Clinical Pharmacology &
Therapeutics, pp. 464–478, 2016.
[6] J. Noe´, R. Portmann, M.-E. Brun, and C. Funk, “Substrate-
dependent drug-drug interactions between gemfibrozil, fluvas-
tatin and other organic anion-transporting peptide (OATP)
substrates on OATP1B1, OATP2B1, and OATP1B3,” Drug Meta-
bolism & Disposition, vol. 35, no. 8, pp. 1308–1314, 2007.
[7] M. V. Varma, K. S. Pang, N. Isoherranen, and P. Zhao, “Dealing
with the complex drug-drug interactions: Towards mechanistic
models,” Biopharmaceutics & Drug Disposition, vol. 36, no. 2,
pp. 71–92, 2015.
[8] A. T. Heikkinen, F. Lignet, P. Cutler, and N. Parrott, “The role
of quantitative ADME proteomics to support construction of
physiologically based pharmacokinetic models for use in small
molecule drug development,” Proteomics - Clinical Applications,
vol. 9, no. 7-8, pp. 732–744, 2015.
[9] R. Li, H. A. Barton, and M. V. Varma, “Prediction of phar-
macokinetics and drug-drug interactions when hepatic trans-
porters are involved,” Clinical Pharmacokinetics, vol. 53, no. 8,
pp. 659–678, 2014.
[10] X. Chu, K. Bleasby, and R. Evers, “Species differences in drug
transporters and implications for translating preclinical find-
ings to humans,” Expert Opinion on Drug Metabolism & Toxi-
cology, vol. 9, no. 3, pp. 237–252, 2013.
[11] T. Takashima, S. Kitamura, Y. Wada et al., “PET imaging-based
evaluation of hepatobiliary transport in humanswith (15R)-11C-
TIC-Me,” Journal of NuclearMedicine, vol. 53, no. 5, pp. 741–748,
2012.
[12] N. W. Ørntoft, O. L. Munk, K. Frisch, P. Ott, S. Keiding, and M.
Sørensen, “Hepatobiliary transport kinetics of the conjugated
bile acid tracer 11C-CSar quantified in healthy humans and
patients by positron emission tomography,” Journal of Hepatol-
ogy, vol. 67, no. 2, pp. 321–327, 2017.
Contrast Media & Molecular Imaging 11
[13] M. F. Alf, M. T. Wyss, A. Buck, B. Weber, R. Schibli, and S.
D. Kra¨mer, “Quantification of brain glucose metabolism by18F-
FDGPETwith real-time arterial and image-derived input func-
tion inmice,” Journal of NuclearMedicine, vol. 54, no. 1, pp. 132–
138, 2013.
[14] G. Warnock, M. Sommerauer, L. Mu et al., “A first-in-man
PET study of [18F]PSS232, a fluorinated ABP688 derivative for
imaging metabotropic glutamate receptor subtype 5,” European
Journal of Nuclear Medicine and Molecular Imaging, pp. 1–11,
2017.
[15] S. D. Kra¨mer, T. Betzel, L. Mu et al., “ Evaluation of ,” Journal of
Nuclear Medicine, vol. 59, no. 4, pp. 698–703, 2018.
[16] A.Mu¨ller, L.Mu, R.Meletta et al., “Towards non-invasive imag-
ing of vulnerable atherosclerotic plaques by targeting co-stimu-
latory molecules,” International Journal of Cardiology, vol. 174,
no. 3, pp. 503–515, 2014.
[17] L. Chen and D. B. Flies, “Molecular mechanisms of T cell co-
stimulation and co-inhibition,” Nature Reviews Immunology,
vol. 13, no. 4, pp. 227–242, 2013.
[18] O. S. Qureshi, Y. Zheng, K. Nakamura et al., “Trans-endocytosis
of CD80 andCD86: amolecular basis for the cell-extrinsic func-
tion of CTLA-4,” Science, vol. 332, no. 6029, pp. 600–603, 2011.
[19] N. J. Green, J. Xiang, J. Chen et al., “Structure-activity studies
of a series of dipyrazolo[3,4-b:3󸀠,4󸀠-d]pyridin-3-ones binding
to the immune regulatory protein B7.1,” Bioorganic &Medicinal
Chemistry, vol. 11, no. 13, pp. 2991–3013, 2003.
[20] P. Huxley, D. H. Sutton, P. Debnam et al., “High-affinity small
molecule inhibitors of T cell costimulation: Compounds for
immunotherapy,” Chemistry & Biology, vol. 11, no. 12, pp. 1651–
1658, 2004.
[21] I. R. Matthews, T. S. Coulter, C. Ghiron et al., “Pyrazoloquino-
lines with immunomodulating activity,” 2004.
[22] K.Hariharan, P. Chu, T.Murphy et al., “Galiximab (anti-CD80)-
induced growth inhibition and prolongation of survival in vivo
of B-NHL tumor xenografts and potentiation by the combina-
tionwith fludarabine,” International Journal of Oncology, vol. 43,
no. 2, pp. 670–676, 2013.
[23] A. L. Goertzen, Q. Bao, M. Bergeron et al., “NEMA NU 4-
2008 comparison of preclinical PET imaging systems,” Journal
of Nuclear Medicine, vol. 53, no. 8, pp. 1300–1309, 2012.
[24] M. Gibaldi and D. Perrier, Pharmacokinetics, CRC Press, Boca
Raton, FL, USA, 2nd edition, 1982.
[25] Jackson Laboratory, “Jax Phenome Database,” January 2018,
https://phenome.jax.org/.
[26] B. Davies and T. Morris, “Physiological parameters in labora-
tory animals and humans,” Pharmaceutical Research, vol. 10, no.
7, pp. 1093–1095, 1993.
[27] PMOD Technologies, PMOD Kinetic Modeling (PKIN),
PMOD Ducumentation, 2017.
[28] R. A. Koeppe, V. A. Holthoff, K. A. Frey, M. R. Kilbourn, and
D. E. Kuhl, “Compartmental analysis of [11C]flumazenil kinet-
ics for the estimation of ligand transport rate and receptor
distribution using positron emission tomography,” Journal of
Cerebral Blood Flow & Metabolism, vol. 11, no. 5, pp. 735–744,
1991.
[29] FDA, “Drug Development and Drug Interactions: Table of Sub-
strates, Inhibitors and Inducers,” 2018.
[30] U. Fagerholm, “Prediction of human pharmacokinetics - Renal
metabolic and excretion clearance,” Journal of Pharmacy and
Pharmacology, vol. 59, no. 11, pp. 1463–1471, 2007.
[31] G. Toffoli, P. Aita, R. Sorio et al., “Effect of cyclosporin A on
protein binding of teniposide in cancer patients,” Anti-Cancer
Drugs, vol. 10, no. 6, pp. 511–518, 1999.
[32] K. M. Wasan, D. R. Brocks, S. D. Lee, K. Sachs-Barrable, and S.
J. Thornton, “Impact of lipoproteins on the biological activity
and disposition of hydrophobic drugs: implications for drug
discovery,” Nature Reviews Drug Discovery, vol. 7, no. 1, pp. 84–
99, 2008.
[33] C. Vanhove, J. P. Bankstahl, S. D. Kra¨mer, E. Visser, N. Belcari,
and S. Vandenberghe, “Accurate molecular imaging of small
animals taking into account animal models, handling, anaes-
thesia, quality control and imaging system performance,” EJN-
MMI Physics, vol. 2, no. 1, article no. 31, pp. 1–25, 2015.
[34] V. Tolmachev, J. Malmberg, C. Hofstro¨m et al., “Imaging of
insulinlike growth factor type 1 receptor in prostate cancer
xenografts using the affibody molecule 111In-DOTA-ZIGF1R:
4551,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 90–97, 2012.
[35] B. Stieger, J. D. Unadkat, B. Prasad, O. Langer, andH.Gali, “Role
of (Drug) transporters in imaging in health and disease,” Drug
Metabolism and Disposition, vol. 42, no. 12, pp. 2007–2015, 2014.
[36] A. Mu¨ller Herde, C. Keller, S. Milicevic Sephton et al., “Quan-
titative positron emission tomography of mGluR5 in rat brain
with [18F]PSS232 at minimal invasiveness and reduced model
complexity,” Journal of Neurochemistry, vol. 133, no. 3, pp. 330–
342, 2015.
[37] V. W. Pike, “Considerations in the development of reversibly
binding pet radioligands for brain imaging,” Current Medicinal
Chemistry, vol. 23, no. 18, pp. 1818–1869, 2016.
[38] B. Testa and S. D. Kra¨mer, “The biochemistry of drug metab-
olism - An introduction part 2. Redox reactions and their en-
zymes,”Chemistry&Biodiversity, vol. 4, no. 3, pp. 257–405, 2007.
[39] Y. Katakura, R. Kishi, T. Okui, T. Ikeda, and H. Miyake, “Dis-
tribution of radioactivity from 14C-formaldehyde in pregnant
mice and their fetuses,” British Journal of Industrial Medicine,
vol. 50, no. 2, pp. 176–182, 1993.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
